Is PT-141 (Bremelanotide) Legal in Colorado?

What Exactly Is PT-141 (Bremelanotide)?

PT-141 is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors, primarily MC3R and MC4R in the central nervous system, to increase sexual desire. Unlike sildenafil or tadalafil, it does not act on the vascular system directly, which is why its mechanism is described as centrally mediated rather than peripheral.

The FDA approved the branded form, VYLEESI (bremelanotide injection, 1.75 mg/0.3 mL), on June 21, 2019, making it one of two approved pharmacologic treatments for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approval letter and prescribing information are publicly accessible on the agency's drug database.

Mechanism and Approved Indication

VYLEESI is injected subcutaneously in the abdomen or thigh 45 minutes before anticipated sexual activity. The prescribing information specifies a maximum of one dose per 24-hour period and no more than approximately one dose per month based on the clinical trial design. The full prescribing information, including boxed warnings and pharmacology data, is hosted by the FDA.

The Phase III Trial Data

The approval rested on two Phase III randomized, placebo-controlled trials, RECONNECT Study 1 and RECONNECT Study 2, each enrolling roughly 600 premenopausal women with generalized acquired HSDD. Across both studies, women using bremelanotide reported a statistically significant increase in satisfying sexual events compared with placebo (P<0.001 for the primary endpoint in each study). The mean change from baseline in the Female Sexual Function Index desire domain score was +0.6 points for bremelanotide versus +0.3 points for placebo in Study 1. The primary RECONNECT trial results were published in Obstetrics and Gynecology in 2019.

Nausea was the most common adverse event, reported in approximately 40% of participants receiving bremelanotide versus 1% on placebo. Transient increases in blood pressure, averaging 2 mmHg systolic and 1 mmHg diastolic, were also documented. These safety findings are detailed in the NEJM evidence review for HSDD pharmacotherapy.

Federal Legal Framework Governing PT-141

FDA-Approved Status vs. Compounded Status

Because VYLEESI holds full FDA approval under NDA 210557, bremelanotide is a legal prescription drug in all 50 states, including Colorado. A licensed prescriber can write a prescription for VYLEESI and a licensed pharmacy can dispense it. That is the cleanest legal pathway.

The more complicated question arises with compounded bremelanotide, where a 503A or 503B facility prepares a non-commercially-available formulation. Federal law under the Drug Quality and Security Act of 2013 permits compounding of drugs that are not "essentially a copy" of an FDA-approved product and are not on the FDA's list of drugs withdrawn from the market for safety reasons. The FDA's compounding oversight page outlines these restrictions.

The 503A and 503B Distinction

A 503A pharmacy compounds for individual patients with a valid, patient-specific prescription from a licensed practitioner. A 503B outsourcing facility may produce larger batches without patient-specific prescriptions but must register with the FDA and comply with current Good Manufacturing Practice. The FDA maintains a current list of registered 503B outsourcing facilities.

Compounded bremelanotide is not explicitly listed on the FDA's 503A bulks prohibition list as of the date of this article's last review. However, the FDA has taken the position that compounding an essentially identical copy of an approved drug like VYLEESI requires clinical justification (e.g., a documented allergy to an excipient in the commercial product or a requirement for a different concentration or route). Compounding pharmacies operating without that documented clinical rationale may attract agency scrutiny. FDA guidance on compounding essentially a copy of an approved drug is published at this FDA guidance document.

Research-Chemical Suppliers: The Gray Zone

Vendors marketing bremelanotide or "PT-141 peptide" as a "research chemical" or "not for human use" occupy a federally uncertain space. The Federal Food, Drug, and Cosmetic Act prohibits the introduction into interstate commerce of any unapproved new drug intended for human use. The FD&C Act statutory text is accessible via the FDA's website. Labeling a product "not for human use" does not legally insulate a seller if the intended use is human administration.

Colorado does not have a separate state-level statute that expressly legalizes research-chemical peptide sales for human use. The absence of a specific Colorado prohibition does not mean the practice is affirmatively legal. Federal law governs drug approval requirements nationwide.

Colorado-Specific Rules

Colorado State Board of Pharmacy

The Colorado State Board of Pharmacy operates under Title 12, Article 280 of the Colorado Revised Statutes. Pharmacies in Colorado that compound prescription products must follow USP Chapter 795 standards for non-sterile preparations and USP Chapter 797 standards for sterile injectables. Bremelanotide is an injectable peptide, so any compounded preparation must meet 797 sterility and beyond-use dating requirements.

Colorado pharmacies compounding bremelanotide for a specific patient under a valid prescription from a Colorado-licensed prescriber are operating within state law, provided the compound is not on the state or federal prohibition list and the pharmacy holds the appropriate licenses. Colorado's pharmacy statutes are published by the Colorado General Assembly.

Colorado Medical Practice Act

Colorado clinicians who prescribe compounded bremelanotide should document the clinical indication clearly. The Colorado Medical Practice Act, Title 12, Article 240, requires that prescribing be within the standard of care. HSDD is a recognized diagnosis under DSM-5, and bremelanotide has a labeled FDA indication, so prescribing the drug is firmly within standard of care for appropriately selected premenopausal women. The Colorado Medical Practice Act is codified in Colorado Revised Statutes Title 12.

Prescribing compounded bremelanotide for off-label indications, such as male sexual dysfunction or use in postmenopausal women, sits outside the labeled indication but is not categorically prohibited. Off-label prescribing is legal under federal and Colorado law. The prescriber bears responsibility for informed consent and documentation.

Telehealth Prescribing in Colorado

Colorado allows telehealth prescribing for non-scheduled medications after a proper evaluation. Bremelanotide is not a DEA-scheduled controlled substance, so a Colorado-licensed telehealth provider can legally evaluate a patient via secure video or asynchronous intake, diagnose HSDD, and issue a prescription without an in-person visit, as long as state telehealth practice standards are met. The Colorado Department of Regulatory Agencies outlines telehealth prescribing standards here. The Colorado Division of Professions and Occupations requires that the telehealth encounter meet the same standard of care as an in-person visit.

How to Get PT-141 (Bremelanotide) in Colorado

Step 1: Establish a Clinical Evaluation

A diagnosis of HSDD requires a clinical assessment that rules out relationship distress, medication-induced sexual dysfunction (SSRIs are a common culprit), hormonal causes such as low testosterone or thyroid dysfunction, and mood disorders. The Decreased Sexual Desire Screener (DSDS) is a validated four-question tool used in clinical practice. Validation data for the DSDS appear in a Journal of Sexual Medicine study accessible on PubMed.

Step 2: Obtain a Prescription from a Licensed Colorado Prescriber

Options include a gynecologist, a primary care physician, or a licensed telehealth platform. The prescriber must be licensed in Colorado and the patient must be located in Colorado at the time of the telehealth encounter. The prescription can specify VYLEESI (the branded product) or a compounded bremelanotide preparation with documented clinical rationale.

Step 3: Use a Licensed Pharmacy

For VYLEESI, any retail pharmacy that stocks it or can order it through a wholesaler will fill the prescription. For compounded bremelanotide, use a pharmacy that holds a Colorado 503A license or a federally registered 503B outsourcing facility. Verifying pharmacy licensure takes under two minutes on the Colorado DORA license lookup portal.

Step 4: Avoid Unregulated Online Vendors

Peptide vendors selling bremelanotide without requiring a prescription are not operating within the FDA-approval framework. Purchasing from these sources does not guarantee purity, sterility, or accurate dosing. An FDA warning letter to a peptide research-chemical company illustrates the agency's enforcement posture.

Dosing and Safety: What Colorado Prescribers Should Know

The table below summarizes the clinical decision framework for bremelanotide prescribing in Colorado, based on FDA labeling and RECONNECT trial data.

| Parameter | Detail | |---|---| | Approved population | Premenopausal women with generalized acquired HSDD | | Dose | 1.75 mg subcutaneous injection | | Timing | 45 minutes before sexual activity | | Frequency cap | One dose per 24 hours; label cautions against chronic daily use | | Contraindications | Known cardiovascular disease; concomitant use of naltrexone (reduced efficacy via opioid receptor interaction) | | Blood pressure monitoring | Baseline CV risk assessment recommended; avoid in uncontrolled hypertension | | Nausea management | Most episodes resolve within 12 hours; dose-reduction strategies vary by compounding formulation | | Off-label male use | No FDA-approved indication; clinical trials in erectile dysfunction showed mixed results |

VYLEESI full prescribing information including contraindications is available on the FDA drug label database.

Blood Pressure Consideration

The transient blood pressure rise documented in RECONNECT is clinically relevant. A mean increase of roughly 2 mmHg systolic sounds modest, but peak increases of up to 6 mmHg systolic have been observed within 4 to 12 hours post-dose in some patients. Cardiovascular safety data from the bremelanotide program are summarized in a Journal of Sexual Medicine review indexed on PubMed.

Prescribers should assess baseline blood pressure at the evaluation visit and document it. Patients with stage 2 hypertension (systolic above 160 mmHg) are generally not appropriate candidates until blood pressure is controlled.

Nausea and Hyperpigmentation

Nausea affects roughly 40% of users. Pre-treating with ondansetron 4 mg orally 30 minutes before the bremelanotide dose is a strategy some clinicians employ, though this combination is off-label and the prescriber should document the rationale. Focal hyperpigmentation of the face, gums, or breasts has been reported with multiple doses. The FDA prescribing information addresses hyperpigmentation risk with chronic use.

Off-Label Uses and Evidence Gaps

Male Sexual Dysfunction

Bremelanotide was originally investigated for erectile dysfunction. Phase II data showed some signal, but the program pivoted to HSDD after the Phase III ED trials did not meet primary endpoints with acceptable tolerability. Early bremelanotide erectile dysfunction trial data are indexed on PubMed. No FDA-approved indication exists for men. Colorado clinicians who prescribe compounded bremelanotide for male patients are prescribing off-label, which is legal but requires documented informed consent.

Postmenopausal Women

The RECONNECT trials enrolled premenopausal women exclusively. Postmenopausal use is off-label. Some clinicians note that estrogen-deficiency-driven low desire may respond better to hormonal correction than to centrally acting melanocortin agonists, but no head-to-head data exist. The North American Menopause Society's position statement on sexual dysfunction management is available at menopause.org.

What Colorado Patients Should Ask Their Prescriber

A productive clinical conversation covers six questions. Is VYLEESI or a compounded preparation more appropriate for this specific patient? Is the pharmacy licensed in Colorado and compliant with USP 797? What is the patient's baseline blood pressure? Are there any medications that could interact (naltrexone, opioid analgesics)? What are the realistic expectations based on RECONNECT trial effect sizes? Has the prescriber ruled out hormonal contributors to low desire, including low testosterone?

The RECONNECT trials showed that bremelanotide increased the number of satisfying sexual events by approximately 0.5 events per month over placebo, a statistically significant but modest absolute effect. That effect size is reported in the primary RECONNECT publication in Obstetrics and Gynecology. Setting accurate expectations is part of informed consent.

As the American College of Obstetricians and Gynecologists states in Committee Opinion 706: "Sexual dysfunction is a common problem affecting women across the life cycle, and clinicians should be prepared to address it in a nonjudgmental manner." ACOG Committee Opinion 706 is referenced at acog.org.